



Jordan



Category Scores




Overall Score in Comparison





Jordan



Key Areas of Strength

- Basic legal framework for major IP rights
- Sector-specific IP rights introduced as part of the 2001 U.S. FTA

Key Areas of Weakness

- No special IP incentives for orphan medicinal product development
- No R&D or IP-specific tax
 incentives are in place
- No targeted incentives for the creation and use of IP assets for SMEs
- High levels of copyright infringement, particularly online
- Uncertainty about the actual availability of the full term of RDP protection; eligibility contingent on global launch and registration in Jordan within 18 months
- Uncertainty about availability
 of patents for CIIs

Indicator	Score
Category 1: Patents Rights and Limitations	5.75
1. Term of protection	1.00
2. Patentability requirements	0.50
3. Patentability of CIIs	0.25
4. Plant variety protection	1.00
5. Pharmaceutical-related enforcement	1.00
Legislative criteria and use of compulsory licensing	1.00
7. Pharmaceutical patent term restoration	1.00
8. Membership of a Patent Prosecution Highway	y 0.00
9. Patent opposition	0.00
Category 2: Copyrights and Limitations	1.94
10. Term of protection	0.44
11. Exclusive rights	0.25
12. Expeditious legal remedies disabling access to infringing content online	0.00
13. Cooperative action against online piracy	0.00
14. Limitations and exceptions	0.50
15. TPM and DRM	0.50
16. Government use of licensed software	0.25
Category 3: Trademarks Rights and Limitations	1.75
17. Term of protection	1.00
18. Protection of well-known marks	0.25
19. Exclusive rights, trademarks	0.25
20. Frameworks against online sale of counterfeit goods	0.25
Category 4: Design Rights and Limitations	0.85
21. Industrial design term of protection	0.60
22. Exclusive rights, industrial design rights	0.25
Category 5: Trade Secrets and the Protection of Confidential Information	1.25
23. Protection of trade secrets (civil remedies)	0.50
24. Protection of trade secrets (criminal sanction	s) 0.25
25. Regulatory data protection term	0.50
Category 6: Commercialization of IP Assets	3.75
26. Barriers to market access	1.00
27. Barriers to technology transfer	0.50
28. Registration and disclosure	
requirements of licensing deals	1.00

Indicator	Score
29. Direct government intervention	1.00
in setting licensing terms 30. IP as an economic asset	1.00 0.25
31. Tax incentives for the creation of IP assets	0.23
Category 7: Enforcement	2.06
32. Physical counterfeiting rates	0.36
33. Software piracy rates	0.45
34. Civil and precedural remedies	0.25
35. Pre-established damages	0.25
36. Criminal standards	0.25
37. Effective border measures	0.50
38. Transparency and public reporting by customs	0.00
Category 8: Systemic Efficiency	1.50
39. Coordination of IP rights enforcement	0.25
40. Consultation with stakeholders during IP policy formation	0.25
41. Educational campaigns and awareness raising	0.20
42. Targeted incentives for the creation	0.00
and use of IP assets for SMEs	0.00
43. IP-intensive industries, national economic impact analysis	0.50
	0.50
Category 9: Cutting-Edge Innovation	0.50
Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal	0.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use 	0.00
Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection	0.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification 	0.00 0.00 0.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development 	0.00 0.00 0.00
Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties	0.00 0.00 0.00
Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties	0.00 0.00 0.00 0.00 3.50
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties 48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement 	0.00 0.00 0.00 0.00 3.50 1.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties 48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks 	0.00 0.00 0.00 3.50 1.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties 48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks 49. Patent Law Treaty and Patent Cooperation Treaty 50. Membership of the International Convention for the Protection of New Varieties of Plants, act of 1991 51. Membership of the Convention 	0.00 0.00 0.00 3.50 1.00 0.00 0.50
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties 48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks 49. Patent Law Treaty and Patent Cooperation Treaty 50. Membership of the International Convention for the Protection of New Varieties of Plants, act of 1991 51. Membership of the Convention on Cybercrime, 2001 52. The Hague Agreement Concerning the 	0.00 0.00 0.00 3.50 1.00 0.50 1.00 0.00
 Category 9: Cutting-Edge Innovation 44. IP incentives for orphan medicinal product development 45. IP incentives for orphan medicinal product development, term of protection 46. Restrictions on the effective use of existing IP incentives for orphan medicinal product development Category 10: Membership and Ratification of International Treaties 47. WIPO Internet Treaties 48. Singapore Treaty on the Law of Trademarks and Protocol Relating to the Madrid Agreement Concerning the International Registration of Marks 49. Patent Law Treaty and Patent Cooperation Treaty 50. Membership of the International Convention for the Protection of New Varieties of Plants, act of 1991 51. Membership of the Convention on Cybercrime, 2001 	0.00 0.00 0.00 0.00 1.00 0.50 1.00

Percentage of Overall Score: 42.17%

Total Score: 22.35

•

Spotlight on the National IP Environment

Past Editions versus Current Score

Jordan's overall Index score remains unchanged at 22.35 out of 53 indicators.

Copyrights and Limitations; Enforcement

11. Legal measures, which provide necessary exclusive rights that prevent infringement of copyrights and related rights (including web hosting, streaming, and linking); 12. Expeditious legal remedies disabling access to infringing content online; and 36. Criminal standards, including minimum imprisonment and minimum fines:

Like many Index economies in the Middle East and North Africa region, the infringement of copyrighted content through set-top boxes and illicit streaming devices is becoming widespread in Jordan. The USTR in both the Review of Notorious Markets for Counterfeiting and Piracy and Special 301 Report have included reference to a Jordanian entity, Spider, which sells pirate set-top boxes and streaming devices. Industry reports suggest that in addition to Spider, several other Jordan-based organizations specialize in the circulation of these devices. The Jordanian Copyright Act provides only basic exclusive rights and does not include specific reference to the internet or mechanisms that address online infringement. No notice-and-takedown system is in place, and there is no established mechanism for gaining injunctive-style relief within the context of copyright infringement. As part of the 2001 U.S.-Jordan FTA, Jordan introduced relevant DRM and TPM legislation. Article 55 of the Copyright Act clearly outlaws the use, sale, manufacture, and distribution of circumvention devices. Still, the scale of both physical and online copyright infringement is substantial, and consistent enforcement efforts are lacking.

As noted last year, some positive developments occurred in 2022 and 2023 with greater enforcement efforts through domestic law enforcement and the disabling of access to pirate websites through the Jordanian Media Commission. Unfortunately, these positive efforts did not carry over into 2024. The Index will continue to monitor this activity in 2025.

Systemic Efficiency

43. IP-intensive industries, national economic impact analysis:

As noted in past editions, the Jordanian Industrial Property Protection Directorate (IPPD) does not have a dedicated research program examining the relationship between IP rights and economic activity. Although IP rights figure only tangentially in national development programs, including the flagship Jordan 2025, A National Vision and Strategy, other examples of government commissioned or supported research examine this relationship, such as the 2012 The Economic Contribution of Copyright-Based Industries in the Hashemite Kingdom of Jordan, a review of the creative economy in Jordan sponsored by WIPO and supported by several parts of the Jordanian Government, including the Ministry of Culture. In 2024, the National Scientific Research and Innovation Support Fund (lodged within the Ministry of Higher Education and Scientific Research) announced that measuring the economic impact of creative and cultural industries in Jordan would be one of its research and funding priorities over the course of the year. The publication of such a study with new, up-to-date data would be an important contribution to better understanding the important role that IP-intensive industries play in Jordan's national economy. The Index will continue to monitor these developments in 2025.

Incentives for Cutting-Edge Innovation

44. Special market exclusivity incentives for orphan medicinal product development; 45. Special market exclusivity incentives for orphan medicinal product development, term of protection; and 46. Restrictions on the effective use of existing market exclusivity incentives for orphan medicinal product development:

Interest in rare diseases has grown in the Middle East and North Africa region. In 2003, the Centre for Arab Genomic Studies was established to map and improve the state of care for patients with genetic diseases in the Arab world. Today, the Center has become the leading research point on rare diseases in the region. Several Index economies in the region, including Saudi Arabia and the UAE, have introduced a defined regulatory sanitary registration pathway and special incentives for orphan products. Jordan does not have in place any special IP-based market exclusivity incentives for orphan medicinal product development.